Media coverage about Xencor (NASDAQ:XNCR) has been trending somewhat positive on Monday, Accern Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Xencor earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 44.6082977044169 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern’s analysis:
- BidaskClub Downgrades Xencor (XNCR) to Strong Sell (americanbankingnews.com)
- Insider Buying: Xencor, Inc. (XNCR) Major Shareholder Purchases 6,215 Shares of Stock (americanbankingnews.com)
- Xencor, Inc. (XNCR) Major Shareholder Buys $191,303.40 in Stock (americanbankingnews.com)
- Xencor, Inc. – Value Analysis (NASDAQ:XNCR) : December 14, 2017 (finance.yahoo.com)
- Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : December 13, 2017 (finance.yahoo.com)
Xencor (XNCR) opened at $21.53 on Monday. Xencor has a 1 year low of $18.55 and a 1 year high of $28.64.
In other news, major shareholder John S. Stafford III bought 9,215 shares of the firm’s stock in a transaction dated Thursday, December 14th. The shares were acquired at an average price of $20.76 per share, for a total transaction of $191,303.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder John S. Stafford III bought 24,653 shares of the firm’s stock in a transaction dated Wednesday, October 25th. The stock was purchased at an average price of $20.01 per share, for a total transaction of $493,306.53. The disclosure for this purchase can be found here. Insiders have acquired 278,535 shares of company stock worth $5,526,936 in the last quarter. 4.03% of the stock is currently owned by company insiders.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.